WASHINGTON — Colchicine does not protect against major cardiovascular adverse events after an acute myocardial infarction, according to a multinational placebo-controlled trial of more than 7000 ...
The colchicine-binding domain (CBD) of tubulin, one of the earliest identified regulatory sites, remains underexplored in oncology despite its proven success in other therapeutic areas. Drugs ...
The Co-STAR trial tested the performance of colchicine in preventing new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. The choice of periprocedural treatment with colchicine was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback